News

    • Precision Antibody Awarded SBIR Contract to Develop High-Affinity, Anti-Peptide Antibodies for SISCAPA Assays

      COLUMBIA, Md., November 4, 2014—Precision Antibody, a market leader in contract antibody services, in partnership with SISCAPA Assay Technologies (SAT), has successfully completed a Phase I SBIR contract from the National Cancer Institute (NCI) to develop high-affinity, anti-peptide antibodies for mass-spectrometry-based serum biomarker detection/quantification assays.

    • Generation monoclonal antibodies against the ECD of transmembrane (TM) receptors

      BOSTON, Ma., Precision Antibody will be attending Discovery on Target Conference on Oct 8-10, 2014. If you need monoclonal antibodies developed against membrane-associated targets such as ECD of receptors and channels, we would encourage you to visit Precision Antibody at Booth #20 at the “Discovery on Target” meeting. Precision Antibody, a market leader in contract antibody services, has an unsurpassed track record generating monoclonal antibodies against the ECD of transmembrane (TM) receptors including single pass and multi-pass receptors.

    • Precision Antibody Expands Antibody Characterization Services

      COLUMBIA, Md., March 15, 2012—Precision Antibody, a market leader in contract antibody services, announced today that they have expanded their antibody characterization services to include Fortebio’s Octet RED96™ system, a multi-functional, label-free, real-time binding analysis instrument.

    • Mayo Medical Laboratories signs agreement with A&G Pharmaceutical, Inc.: Mayo Clinic Announces Collaboration on New Progranulin Blood Test for Dementia

      ROCHESTER, Minn., March 6, 2012—Mayo Clinic today announced that it has signed an agreement with A&G Pharmaceutical, Inc. and will receive a non-exclusive license to certain patent rights and proprietary antibody reagents for the detection and measurement of progranulin in blood. This agreement will enable Mayo Clinic to offer the first commercial blood test to predict progranulin mutation status in patients suspected of frontotemporal dementia (FTD).

    • FDA Awards Precision Antibody Contract to Develop Monoclonal Antibodies for Influenza Vaccine Potency Assays

      COLUMBIA, Md., October 20, 2011—Precision Antibody™ announced today its selection by the United States Food and Drug Administration (FDA) to develop monoclonal antibodies to influenza virus antigens for both Influenza A and B. These antibodies will be used for in vitro assays to develop new vaccine potency assays. The term of the monoclonal development and antibody production contract is for one year with the option of five additional years.

    • EPA Awards Precision Antibody Contract to Develop Monoclonal Antibodies for Detection of Parasites in Water Resources

      COLUMBIA, Md., August 23, 2010—Precision Antibody™announced today its selection by the United States Environmental Protection Agency (EPA) to develop monoclonal antibodies to two species of Cryptosporidium (“Crypto”), an intestinal parasite that has emerged over the past 20 years as one of the most common causes of waterborne illness in the United States. According to the U.S. Centers for Disease Control and Prevention, between 2006–2008, Crypto was responsible for 42 percent of reported recreational water-associated gastroenteritis in the United States, and six percent of reported drinking water-associated outbreaks. The development of antibodies that substantially improve the sensitivity and specific detection and typing of this parasite over currently available methods may lead to improved tests for detecting Crypto in drinking water supplies and recreational waters as well as the potential to develop effective treatments for people infected by the pathogen.

    • Precision Antibody Selected to Provide Antibody Characterization for National Cancer Institute’s Clinical Proteomics Technologies for Cancer (CPTC) Initiative

      COLUMBIA, Md., July 21, 2010—Precision Antibody™ announced today its selection by Science Applications International Corporation–Frederick (SAIC-F) to provide antibody and antigen characterization, including surface plasmon resonance (SPR) analysis, for the National Cancer Institute’s “Clinical Proteomic Technologies for Cancer” (CPTC) initiative (www.proteomics.cancer.gov). A goal of the CPTC is to develop a standardized resource of very high-quality, renewable reference antibodies generated against cancer-related proteins. The antibodies will be made available to proteomics researchers, along with characterization data and other information intended to support replication and standardization.

    • Precision Antibody to Develop Antibodies for NCI's Proteomic's Initiative

      COLUMBIA, Md., October 27, 2009—Precision Antibody™ has been selected as the antibody developer for a component of the National Cancer Institute (NCI)’s Clinical Proteomic Technologies for Cancer (CPTC), which is focused on improving the number and standardizing the quality of monoclonal antibody reagents available for clinical cancer proteomics research. The contract award is the result of a third solicitation for contract proposals from custom antibody suppliers as part of the Clinical Proteomic Reagents Resources component of the CPTC, whose mission is to develop high-quality, standardized, renewable reagents that are needed for effective proteomic analysis.